FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285405341> ?p ?o ?g. }

• W4285405341 endingPage "10" @default.
• W4285405341 startingPage "1" @default.
• W4285405341 abstract "PurposePeople living with cancer and haematological malignancies are at an increased risk of hospitalisation and death following infection with acute respiratory syndrome coronavirus 2. Coronavirus third dose vaccine boosters are proposed to boost waning immune responses in immunocompromised individuals and increase coronavirus protection; however, their effectiveness has not yet been systematically evaluated.MethodsThis study is a population-scale real-world evaluation of the United Kingdom’s third dose vaccine booster programme for cancer patients from 8th December 2020 to 7th December 2021. The cancer cohort comprises individuals from Public Health England’s national cancer dataset, excluding individuals less than 18 years. A test-negative case-control design was used to assess the third dose booster vaccine effectiveness. Multivariable logistic regression models were fitted to compare risk in the cancer cohort relative to the general population.ResultsThe cancer cohort comprised of 2,258,553 tests from 361,098 individuals. Third dose boosters were evaluated by reference to 87,039,743 polymerase chain reaction coronavirus tests. Vaccine effectiveness against breakthrough infections, symptomatic infections, coronavirus hospitalisation and death in cancer patients were 59.1%, 62.8%, 80.5% and 94.5%, respectively. Lower vaccine effectiveness was associated with a cancer diagnosis within 12 months, lymphoma, recent systemic anti-cancer therapy (SACT) or radiotherapy. Patients with lymphoma had low levels of protection from symptomatic disease. In spite of third dose boosters, following multivariable adjustment, individuals with cancer remain at an increased risk of coronavirus hospitalisation and death compared to the population control (OR 3.38, 3.01, respectively. p < 0.001 for both).ConclusionsThird dose boosters are effective for most individuals with cancer, increasing protection from coronavirus. However, their effectiveness is heterogenous and lower than the general population. Many patients with cancer will remain at the increased risk of coronavirus infections even after 3 doses. In the case of patients with lymphoma, there is a particularly strong disparity of vaccine effectiveness against breakthrough infection and severe disease. Breakthrough infections will disrupt cancer care and treatment with potentially adverse consequences on survival outcomes. The data support the role of vaccine boosters in preventing severe disease, and further pharmacological intervention to prevent transmission and aid viral clearance to limit the disruption of cancer care as the delivery of care continues to evolve during the coronavirus pandemic." @default.
• W4285405341 created "2022-07-14" @default.
• W4285405341 creator A5001537432 @default.
• W4285405341 creator A5005755138 @default.
• W4285405341 creator A5006023474 @default.
• W4285405341 creator A5007119947 @default.
• W4285405341 creator A5009387241 @default.
• W4285405341 creator A5011975193 @default.
• W4285405341 creator A5013407969 @default.
• W4285405341 creator A5016184299 @default.
• W4285405341 creator A5018138070 @default.
• W4285405341 creator A5018304588 @default.
• W4285405341 creator A5018955337 @default.
• W4285405341 creator A5021189367 @default.
• W4285405341 creator A5023781617 @default.
• W4285405341 creator A5024021926 @default.
• W4285405341 creator A5024626262 @default.
• W4285405341 creator A5024644075 @default.
• W4285405341 creator A5025872990 @default.
• W4285405341 creator A5026029244 @default.
• W4285405341 creator A5026300918 @default.
• W4285405341 creator A5028056027 @default.
• W4285405341 creator A5030998318 @default.
• W4285405341 creator A5031288050 @default.
• W4285405341 creator A5031563579 @default.
• W4285405341 creator A5032238028 @default.
• W4285405341 creator A5033458280 @default.
• W4285405341 creator A5036322189 @default.
• W4285405341 creator A5036792587 @default.
• W4285405341 creator A5039547041 @default.
• W4285405341 creator A5044152755 @default.
• W4285405341 creator A5050007456 @default.
• W4285405341 creator A5050042532 @default.
• W4285405341 creator A5053312699 @default.
• W4285405341 creator A5054875746 @default.
• W4285405341 creator A5055393004 @default.
• W4285405341 creator A5056436213 @default.
• W4285405341 creator A5058181002 @default.
• W4285405341 creator A5060103910 @default.
• W4285405341 creator A5060745117 @default.
• W4285405341 creator A5060874134 @default.
• W4285405341 creator A5061955921 @default.
• W4285405341 creator A5062742458 @default.
• W4285405341 creator A5063446952 @default.
• W4285405341 creator A5065587850 @default.
• W4285405341 creator A5067553302 @default.
• W4285405341 creator A5068571946 @default.
• W4285405341 creator A5069199705 @default.
• W4285405341 creator A5072681000 @default.
• W4285405341 creator A5075355104 @default.
• W4285405341 creator A5075861422 @default.
• W4285405341 creator A5076753836 @default.
• W4285405341 creator A5078670670 @default.
• W4285405341 creator A5079264223 @default.
• W4285405341 creator A5080131386 @default.
• W4285405341 creator A5080679155 @default.
• W4285405341 creator A5083238717 @default.
• W4285405341 creator A5084004538 @default.
• W4285405341 creator A5084754710 @default.
• W4285405341 creator A5087262350 @default.
• W4285405341 creator A5089769159 @default.
• W4285405341 creator A5090975237 @default.
• W4285405341 date "2022-11-01" @default.
• W4285405341 modified "2023-10-09" @default.
• W4285405341 title "COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study" @default.
• W4285405341 cites W3028965239 @default.
• W4285405341 cites W3030573714 @default.
• W4285405341 cites W3080162924 @default.
• W4285405341 cites W3157453497 @default.
• W4285405341 cites W3158078097 @default.
• W4285405341 cites W3160138987 @default.
• W4285405341 cites W3173150656 @default.
• W4285405341 cites W3174588189 @default.
• W4285405341 cites W3176215631 @default.
• W4285405341 cites W3184226105 @default.
• W4285405341 cites W3186315581 @default.
• W4285405341 cites W3195694100 @default.
• W4285405341 cites W3201836196 @default.
• W4285405341 cites W3212193373 @default.
• W4285405341 cites W3213230441 @default.
• W4285405341 cites W3214040109 @default.
• W4285405341 cites W3215030919 @default.
• W4285405341 cites W3215637620 @default.
• W4285405341 cites W4200338464 @default.
• W4285405341 cites W4200380160 @default.
• W4285405341 cites W4207003944 @default.
• W4285405341 cites W4220763807 @default.
• W4285405341 cites W4220932802 @default.
• W4285405341 cites W4225569559 @default.
• W4285405341 cites W4226024281 @default.
• W4285405341 cites W4281399377 @default.
• W4285405341 cites W4281648196 @default.
• W4285405341 doi "https://doi.org/10.1016/j.ejca.2022.06.038" @default.
• W4285405341 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36084618" @default.
• W4285405341 hasPublicationYear "2022" @default.
• W4285405341 type Work @default.
• W4285405341 citedByCount "28" @default.
• W4285405341 countsByYear W42854053412022 @default.

• next